Spruce Capital Partners, based in San Francisco, was founded in 2013 and has a track record of committing exits more frequently than other organizations. The firm typically invests in deals ranging from $10 to $50 million and has a preference for startups in the health care and medical sectors. They tend to invest in companies that are 2-3 years old and participate in rounds with 5-6 participants. The principals of Spruce Capital Partners are experienced investors and thought leaders in the biogreentech sector, and they actively work with the life sciences industry globally, particularly in Malaysia and the United States. Their portfolio includes companies such as Evolve BioSystems, Provivi, and Inscripta, Inc.